Are you looking for the next great pet stock play?
Don't miss this opportunity as FRPT is already trading over 100 dollars per share!
Read more here about the next great pet stock!

APVO Insider Trading (Aptevo Therapeutics)

Insider Ownership Percentage: 10.88%
Insider Buying (Last 12 Months): $13,097,602.46
Insider Selling (Last 12 Months): $0.00

Aptevo Therapeutics Insider Trading History Chart

Aptevo Therapeutics Share Price & Price History

▼ -1.14 (-3.31%)
As of 02/24/2021 01:00 AM ET
Days: 30 | 90 | 365
Are you looking for the next great pet stock play?
Don't miss this opportunity as FRPT is already trading over 100 dollars per share!
Read more here about the next great pet stock!

Aptevo Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/6/2020Kevin C TangMajor ShareholderBuy174,277$22.73$3,961,316.21  
11/4/2020Kevin C TangMajor ShareholderBuy636,675$14.35$9,136,286.25  
8/16/2019Randy Joe MadduxCMOBuy25,000$0.76$19,000.0075,000  
8/12/2019Fuad El-HibriDirectorBuy100,000$0.76$76,000.001,124,536  
7/29/2019Fuad El-HibriDirectorBuy55,015$0.83$45,662.451,024,536  
7/22/2019Fuad El-HibriDirectorBuy30,000$0.89$26,700.00959,521  
7/18/2019Fuad El-HibriDirectorBuy14,404$0.87$12,531.48903,061  
7/16/2019Fuad El-HibriDirectorBuy11,375$0.85$9,668.75869,521  
7/10/2019Fuad El-HibriDirectorBuy18,919$0.85$16,081.15843,455  
6/25/2019Daniel Abdun-NabiDirectorBuy16,667$0.90$15,000.30109,351  
6/14/2019Marvin L WhiteCEOBuy50,000$0.88$44,000.00293,603  
6/10/2019Barbara Lopez KunzDirectorBuy10,000$0.85$8,500.0010,000  
6/7/2019Zsolt HarsanyiDirectorBuy50,000$0.78$39,000.0050,000  
5/31/2019Randy Joe MadduxVPBuy20,000$0.73$14,600.0050,000  
5/21/2019Grady Grant IIIDirectorBuy10,000$0.80$8,000.0010,000  
5/20/2019Marvin L WhiteCEOBuy30,000$0.81$24,300.00243,603  
5/14/2019Marvin L WhiteInsiderBuy10,000$0.78$7,800.00213,603  
12/6/2018Randy Joe MadduxSVPBuy5,000$2.37$11,850.0030,000  
12/4/2018Marvin L WhiteInsiderBuy10,000$2.38$23,800.00203,603  
3/19/2018Marvin L WhiteInsiderSell100,000$2.93$293,000.00  
See Full Table

SEC Filings (Institutional Ownership Changes) for Aptevo Therapeutics (NASDAQ:APVO)

14.06% of Aptevo Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Aptevo Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
2/24/2021Alyeska Investment Group L.P.49,601$1.82M0.0%N/A1.133%
2/18/2021Ghost Tree Capital LLC50,000$1.83M0.4%N/A1.142%
2/16/2021Alyeska Investment Group L.P.49,601$1.82M0.0%N/A1.133%
2/16/2021Pura Vida Investments LLC8,203$0.30M0.0%N/A0.187%
2/16/2021Price T Rowe Associates Inc. MD6,300$0.23M0.0%N/A0.144%
2/12/2021Stonepine Capital Management LLC18,280$0.67M0.5%N/A0.417%
2/11/2021JBF Capital Inc.2,607$96K0.0%N/A0.060%
2/11/2021Northern Trust Corp8,707$0.32M0.0%N/A0.199%
2/11/2021Citigroup Inc.967$35K0.0%N/A0.022%
2/11/2021Dynamic Technology Lab Private Ltd13,202$0.48M0.1%N/A0.301%
2/10/2021Renaissance Technologies LLC254,423$9.33M0.0%-13.1%5.810%
2/9/2021Wells Fargo & Company MN1,552$57K0.0%+241.1%0.035%
2/5/2021BlackRock Inc.58,168$2.13M0.0%+166.8%1.328%
11/16/2020Worth Venture Partners LLC27,645$0.21M0.2%-21.8%0.667%
11/9/2020Acadian Asset Management LLC45,126$0.34M0.0%-2.5%1.396%
11/6/2020GSA Capital Partners LLP40,512$0.31M0.1%N/A1.253%
8/5/2020WINTON GROUP Ltd11,332$95K0.0%N/A0.351%
7/31/2020UBS Group AG10,015$83K0.0%-13.3%0.310%
5/1/2020BlackRock Inc.21,968$81K0.0%-92.8%0.679%
5/1/2020UBS Group AG11,548$43K0.0%-93.4%0.358%
2/14/2020Bank of New York Mellon Corp56,181$37K0.0%-44.2%0.124%
2/14/2020UBS Group AG175,092$0.12M0.0%+27.3%0.387%
2/13/2020Renaissance Technologies LLC2,379,859$1.56M0.0%+9.8%5.256%
11/27/2019Point72 Asset Management L.P.2,450,000$1.44M0.0%+4.3%5.411%
8/14/2019Point72 Asset Management L.P.2,350,000$2.08M0.0%+6.8%5.211%
8/14/2019Worth Venture Partners LLC447,669$0.40M0.2%+4.4%0.993%
8/14/2019Algert Global LLC74,906$66K0.0%N/A0.166%
8/14/2019Vanguard Group Inc.1,122,138$0.99M0.0%-24.5%2.489%
8/14/2019A.R.T. Advisors LLC131,134$0.12M0.0%+203.5%0.291%
8/13/2019Stonepine Capital Management LLC3,922,891$3.48M2.4%+0.7%8.700%
8/13/2019BlackRock Inc.305,365$0.27M0.0%-13.7%0.677%
8/12/2019Renaissance Technologies LLC1,644,856$1.46M0.0%+32.9%3.648%
8/12/2019Bank of New York Mellon Corp56,620$50K0.0%+256.3%0.126%
8/8/2019Acadian Asset Management LLC632,507$0.56M0.0%+312.8%1.403%
6/16/2019Marshall Wace LLP36,569$33K0.0%N/A0.081%
4/1/2019Deutsche Bank AG330,200$0.42M0.0%+251.7%0.769%
2/14/2019Park West Asset Management LLC165,520$0.21M0.0%-66.9%0.726%
2/13/2019Dimensional Fund Advisors LP1,442,049$1.83M0.0%+1.2%6.323%
2/13/2019Clifford Swan Investment Counsel LLC27,200$35K0.0%N/A0.119%
2/7/2019Acadian Asset Management LLC462,824$0.59M0.0%+4.8%2.029%
11/15/2018Sessa Capital IM L.P.706,613$3.59M0.5%+35.9%3.117%
11/13/2018Renaissance Technologies LLC1,277,100$6.49M0.0%+11.1%5.633%
11/13/2018Dimensional Fund Advisors LP1,425,567$7.24M0.0%+5.5%6.288%
11/13/2018Alambic Investment Management L.P.70,517$0.36M0.3%-39.4%0.311%
11/7/2018JPMorgan Chase & Co.76,339$0.39M0.0%-73.7%0.337%
10/30/2018Acadian Asset Management LLC441,765$2.24M0.0%+20.2%1.949%
9/18/2018Northern Trust Corp70,416$0.35M0.0%+21.2%0.311%
8/14/2018Alambic Investment Management L.P.116,427$0.58M0.2%-41.1%0.514%
8/13/2018Renaissance Technologies LLC1,149,400$5.74M0.0%+53.3%5.088%
8/10/2018Dimensional Fund Advisors LP1,351,656$6.75M0.0%+10.8%5.983%
8/3/2018EAM Investors LLC110,584$0.55M0.1%N/A0.490%
8/2/2018Connor Clark & Lunn Investment Management Ltd.29,650$0.15M0.0%N/A0.131%
7/24/2018Acadian Asset Management LLC367,509$1.83M0.0%+79.0%1.627%
5/16/2018Millennium Management LLC96,891$0.32M0.0%-54.9%0.429%
5/15/2018Park West Asset Management LLC184,629$0.60M0.0%N/A0.817%
5/11/2018Citadel Advisors LLC39,653$0.13M0.0%+215.4%0.177%
5/11/2018Dimensional Fund Advisors LP1,219,852$3.99M0.0%+11.2%5.436%
5/10/2018JPMorgan Chase & Co.254,282$0.83M0.0%+346.6%1.133%
5/10/2018Spark Investment Management LLC129,400$0.42M0.0%+82.8%0.577%
5/8/2018Alambic Investment Management L.P.197,617$0.65M0.1%N/A0.881%
5/4/2018Victory Capital Management Inc.215,110$0.70M0.0%+10.3%0.959%
2/15/2018Millennium Management LLC214,782$0.91M0.0%-28.4%1.002%
2/14/2018Sessa Capital IM L.P.1,628,053$6.90M0.8%-15.2%7.594%
2/13/2018Renaissance Technologies LLC428,400$1.82M0.0%+411.8%1.998%
2/12/2018Spark Investment Management LLC70,800$0.30M0.0%-34.5%0.330%
2/9/2018Virtu Financial LLC162,689$0.69M0.0%N/A0.759%
2/9/2018BlackRock Inc.350,913$1.49M0.0%-33.0%1.637%
2/1/2018Victory Capital Management Inc.195,110$0.83M0.0%N/A0.910%
1/18/2018Acadian Asset Management LLC67,799$0.29M0.0%+87.2%0.316%
11/13/2017Dimensional Fund Advisors LP893,338$2.05M0.0%-15.5%4.171%
8/15/2017CNH Partners LLC132,502$0.27M0.0%No Change0.619%
8/14/2017Goldman Sachs Group Inc.92,550$0.19M0.0%-20.8%0.432%
8/14/2017Precept Management LLC584,449$1.21M0.7%N/A2.729%
8/11/2017Dimensional Fund Advisors LP1,056,729$2.19M0.0%+8.0%4.985%
8/11/2017FMR LLC741,267$1.53M0.0%+0.0%3.497%
8/3/2017Legal & General Group Plc393,701$0.82M0.0%+11,751.3%1.857%
7/27/2017Spark Investment Management LLC61,500$0.13M0.0%+167.4%0.290%
Data available starting January 2016

See Full Table
Aptevo Therapeutics logo
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $33.27

50 Day Range

MA: $35.25

52 Week Range

Now: $33.27


45,805 shs

Average Volume

71,158 shs

Market Capitalization

$145.69 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Aptevo Therapeutics?

Aptevo Therapeutics' top insider shareholders include:
  1. Fuad El-Hibri (Director)
  2. Marvin L White (CEO)
  3. Marvin L White (Insider)
  4. Daniel Abdun-Nabi (Director)
  5. Randy Joe Maddux (CMO)
  6. Randy Joe Maddux (VP)
  7. Zsolt Harsanyi (Director)
  8. Barbara Lopez Kunz (Director)
  9. Grady Grant III (Director)
  10. Kevin C Tang (Major Shareholder)

Who are the major institutional investors of Aptevo Therapeutics?

Aptevo Therapeutics' top institutional investors include:
  1. Renaissance Technologies LLC — 5.81%
  2. BlackRock Inc. — 1.33%
  3. Ghost Tree Capital LLC — 1.14%
  4. Alyeska Investment Group L.P. — 1.13%
  5. Alyeska Investment Group L.P. — 1.13%
  6. Stonepine Capital Management LLC — 0.42%

Which major investors are selling Aptevo Therapeutics stock?

During the previous quarter, APVO stock was sold by these institutional investors:
  1. Renaissance Technologies LLC

Which major investors are buying Aptevo Therapeutics stock?

Within the last quarter, APVO stock was purchased by institutional investors including:
  1. Ghost Tree Capital LLC
  2. Alyeska Investment Group L.P.
  3. Alyeska Investment Group L.P.
  4. BlackRock Inc.
  5. Stonepine Capital Management LLC
  6. Dynamic Technology Lab Private Ltd
  7. Northern Trust Corp
  8. Pura Vida Investments LLC
Within the previous year, these company insiders have bought Aptevo Therapeutics stock:
  1. Fuad El-Hibri (Director)
  2. Marvin L White (CEO)
  3. Marvin L White (Insider)
  4. Daniel Abdun-Nabi (Director)
  5. Randy Joe Maddux (CMO)
  6. Randy Joe Maddux (VP)
  7. Zsolt Harsanyi (Director)
  8. Barbara Lopez Kunz (Director)
  9. Grady Grant III (Director)
  10. Kevin C Tang (Major Shareholder)
Are you looking for the next great pet stock play?
Don't miss this opportunity as FRPT is already trading over 100 dollars per share!
Read more here about the next great pet stock!